Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2868576 | 0.93 | SRD5A2 (0.45) | ESR1SLC6A9PPARGPPARDPPARA | |
| SCHEMBL2863721 | 0.93 | FFAR4 (0.44) | ESR1FFAR4FFAR1SLC6A9PPARG | |
| SCHEMBL2866399 | 0.88 | FFAR4 (0.41) | ESR1FFAR4FFAR1SLC6A9PPARG | |
| SCHEMBL2870973 | 0.86 | SRD5A2 (0.46) | ESR1SLC6A9PPARGPPARDPPARA | |
| SCHEMBL2864817 | 0.83 | SRD5A2 (0.45) | ESR1PPARGPPARDPPARASRD5A2 | |
| SCHEMBL2866515 | 0.83 | SRD5A2 (0.45) | FFAR4FFAR1PPARGPPARDPPARA | |
| SCHEMBL2863528 | 0.82 | ESR1 (0.44) | ESR1FFAR4FFAR1SLC6A9PPARG | |
| SCHEMBL2871484 | 0.81 | SRD5A2 (0.47) | FFAR1SRD5A2 | |
| SCHEMBL2872127 | 0.80 | SMN1; SMN2 (0.46) | SRD5A2THRAS1PR1S1PR3 | |
| SCHEMBL2871447 | 0.78 | THRA (0.50) | THRAS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691898-B2 | Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1813620-A1 | PHOSPHONIC ACID DERIVATIVE AND THERAPEUTIC AGENT FOR DISEASE IN WHICH HIGH PHOSPHATE LEVEL IN BLOOD PARTICIPATES | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | NR0B1, NR0B2, PTH1R | ESR1 105/4885FFAR4 1541/4885FFAR1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.